difelikefalin (Rx)

Brand and Other Names:Korsuva
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 65mcg/1.3mL

Pruritus

Indicated for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis (HD)

0.5 mcg/kg IV push into venous line of dialysis circuit at the end of each HD treatment

Dosage Modifications

Hepatic impairment

  • Mild-to-moderate: No dosage adjustment needed
  • Severe: Pharmacokinetics not evaluated; use not recommended

Dosing Considerations

Limitation of use

  • Not studied in patients on peritoneal dialysis; use not recommended

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and difelikefalin

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (0)

                  Minor (0)

                    Previous
                    Next:

                    Adverse Effects

                    1-10%

                    Diarrhea (9%)

                    Dizziness (6.8%)

                    Nausea (6.6%)

                    Gait disturbances (6.6%)

                    Hyperkalemia (4.7%)

                    Headache (4.5%)

                    Somnolence (4.2%)

                    Mental status change (3.3%)

                    Previous
                    Next:

                    Warnings

                    Contraindications

                    None

                    Cautions

                    Dizziness, somnolence, mental status changes, and gait disturbances (eg, falls) have occurred; may subside over time with continued treatment

                    May impair mental or physical abilities; advise patients not to drive or operate dangerous machinery until effect on a patient’s ability to drive or operate machinery is known

                    Drug interaction overview

                    • Centrally acting depressant medications, sedating antihistamines, and opioid analgesics may increase the adverse reactions of difelikefalin; use with caution
                    Previous
                    Next:

                    Pregnancy & Lactation

                    Pregnancy

                    Limited human data are insufficient on use in pregnant females to evaluate drug-associated risks for major birth defects or miscarriage

                    Lactation

                    There are no data regarding drug presence in human milk, effects on breastfed infants, or effects on milk production

                    Studies showed difelikefalin was transferred into milk in lactating rats

                    When a drug is present in animal milk, it is likely that the drug will be present in human milk

                    Pregnancy Categories

                    A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                    B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                    C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                    D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                    X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                    NA: Information not available.

                    Previous
                    Next:

                    Pharmacology

                    Mechanism of Action

                    Kappa opioid receptor (KOR) agonist

                    Relevance of KOR activation to therapeutic effectiveness is unknown

                    Absorption

                    Steady-state was reached after second dose

                    Mean accumulation ratio: 1.6

                    Distribution

                    Vd: 238 mL/kg

                    Protein bound: 23-28%

                    Elimination

                    Half-life (before dialysis): 23-31 hr

                    Excretion: Urine (11%); feces (59%); dialysate fluid (20%)

                    Previous
                    Next:

                    Administration

                    IV Preparation

                    Do not mix or dilute before administration

                    Visually inspect vials for particulate matter and discoloration before administering; solution should be clear and colorless; discard vials if particulate matter or discoloration is observed

                    Vials are for single-dose use; discard any unused product

                    May use the following formula to determine total injection volume on target body weight or may refer to prescribing information

                    Total injection volume (mL) = Patient target dry body weight (kg) x 0.01, rounded to the nearest tenth (0.1 mL)

                    IV Administration

                    Administer after blood is no longer circulating through the dialyzer; dialyzer membrane removes difelikefalin

                    Administer IV push into venous line of the dialysis circuit at the end of each HD session

                    May be given either during or after rinse back of dialysis circuit

                    Dose given after rinse back: Administer into venous line followed by ≥10 mL of 0.9% NaCl flush

                    Dose given during rinse back: No additional 0.9% NaCl is needed to flush line

                    Administer within 60 minutes of syringe preparation; discard any unused product

                    Missed regularly scheduled HD treatment: Resume at the end of next HD treatment

                    Storage

                    Unopened vials

                    • Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)
                    • Do not freeze

                    Prepared syringe

                    • Store at 20-25ºC (68-77ºF); discard after 60 minutes of syringe preparation
                    Previous
                    Next:

                    Images

                    No images available for this drug.
                    Previous
                    Next:

                    Patient Handout

                    A Patient Handout is not currently available for this monograph.
                    Previous
                    Next:

                    Formulary

                    FormularyPatient Discounts

                    Adding plans allows you to compare formulary status to other drugs in the same class.

                    To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                    Adding plans allows you to:

                    • View the formulary and any restrictions for each plan.
                    • Manage and view all your plans together – even plans in different states.
                    • Compare formulary status to other drugs in the same class.
                    • Access your plan list on any device – mobile or desktop.

                    The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                    Tier Description
                    1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                    2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                    3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                    4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    NC NOT COVERED – Drugs that are not covered by the plan.
                    Code Definition
                    PA Prior Authorization
                    Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                    QL Quantity Limits
                    Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                    ST Step Therapy
                    Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                    OR Other Restrictions
                    Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                    Additional Offers
                    Email to Patient

                    From:

                    To:

                    The recipient will receive more details and instructions to access this offer.

                    By clicking send, you acknowledge that you have permission to email the recipient with this information.

                    Email Forms to Patient

                    From:

                    To:

                    The recipient will receive more details and instructions to access this offer.

                    By clicking send, you acknowledge that you have permission to email the recipient with this information.

                    Previous
                    Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.